Related Experiment Video

Updated: Jan 5, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.0K

Antidiabetic therapies and Alzheimer disease

Barbara B Bendlin1

  • 1School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Dialogues in Clinical Neuroscience
|October 15, 2019
PubMed

Insights

Type 2 diabetes increases dementia risk. This review examines how antidiabetic medications may affect dementia risk and cognitive function, exploring their potential for prevention and treatment.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Gerontology

Background:

  • Dementia, including Alzheimer disease, lacks effective therapies, driving interest in modifiable risk factors.
  • Type 2 diabetes is linked to increased dementia risk, prompting investigation into antidiabetic medications.
  • Cardiovascular risks, diet, and physical activity are also recognized modifiable factors.

Purpose of the Study:

  • To review the association between type 2 diabetes and dementia risk.
  • To evaluate evidence on antidiabetic treatments' impact on dementia risk and cognitive function.
  • To summarize findings from clinical trials of antidiabetic drugs in Alzheimer disease.

Main Methods:

  • Literature review of studies on diabetes, antidiabetic medications, and dementia.
  • Analysis of epidemiological data and clinical trial results.
  • Synthesis of current evidence on treatment mechanisms and outcomes.

Main Results:

  • Established link between type 2 diabetes and elevated dementia risk.
  • Mixed evidence regarding antidiabetic medications' protective or detrimental effects on cognition.
  • Ongoing research exploring therapeutic potential in Alzheimer disease.

Conclusions:

  • Understanding the diabetes-dementia link is crucial for developing preventive and therapeutic strategies.
  • Further research is needed to clarify the role of antidiabetic treatments in dementia.
  • Modifiable factors, including diabetes management, offer potential avenues for mitigating dementia risk.

Keywords:
APOE ε4Alzheimer diseasebiomarkerclinical trialdementiametforminrisktype 2 diabetes

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.5K
Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.0K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
731
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
828
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
550
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
493
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
537